

Lotilaner/Milbemycin Elanco 225 mg + 8.44 mg - Chewable tablet

Authorised

- Lotilaner
- Milbemycin oxime

Product identification

Medicine name:

Lotilaner/Milbemycin Elanco 225 mg + 8.44 mg - Chewable tablet

Active substance:

Lotilaner

Milbemycin oxime

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Lotilaner

Presentation_strength:225 mg Reference:In house Index:0

Milbemycin oxime

Presentation_strength:8.44 mg Reference:Ph. Eur. Index:1

Pharmaceutical form:

Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP54AB51

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging:Blister (alu), Package_size:3 tablets

Packaging:Blister (alu), Package_size:18 tablets

Packaging:Blister (alu), Package_size:6 tablets

Packaging:Blister (alu), Package_size:1 tablet

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Informed Consent application (Article 21 of Regulation (EU) 2019/6)

Marketing authorisation holder:

Elanco GmbH

Marketing authorisation date:

25/02/2026

Manufacturing sites for batch release:

Elanco France S.A.S.

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

25/02/2026

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 9/03/2026

[Download](#)